Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. on April 4, 2016. The report details a strategic operational change regarding the company's independent registered public accounting firm, aligning with the company's migration to become a U.S.-centered biotechnology entity.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and auditor changes rather than financial performance data.
Material Changes
- Dismissal of Auditor: On April 4, 2016, the Audit Committee approved the immediate dismissal of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft ("E&Y GmbH"), the German member firm that had traditionally serviced the company.
- Engagement of New Auditor: Simultaneously, the Audit Committee engaged Ernst & Young LLP ("E&Y LLP"), the U.S. member firm, as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Audit History: Reports issued by E&Y GmbH for fiscal years 2014 and 2015 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: There were no disagreements with E&Y GmbH on accounting principles, practices, or auditing scope during the relevant periods.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlooks, or specific risk factors beyond the context of the auditor transition. Management commentary indicates the change was deemed appropriate to support the company's shift to a U.S.-centered structure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the effective date of the auditor transition (April 4, 2016).
- Confirm the identity of the new auditor (Ernst & Young LLP) versus the former auditor (Ernst & Young GmbH).
- Review the attached letter from E&Y GmbH (Exhibit 16.1) to ensure they concur with the disclosures regarding the dismissal.
- Note that the filing explicitly states no consultations occurred with E&Y LLP regarding accounting principles or disagreements prior to engagement.